Drug
Apitolisib clinical trials
Also written GDC-0980.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Ipatasertib (1) · Rabeprazole (1) · Pictilisib (1) · Ketoconazole (1)
Studies
Open first, then newest update. How each study uses apitolisib is read from its arms, and is right about nine times in ten.
Testing it · 9
- Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyCompletedPhase 1/2Genentech, Inc.NCT01485861Written as Apitolisib
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the TabletCompletedPhase 1Genentech, Inc.NCT01287091Written as GDC-0980
- Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyCompletedPhase 2Genentech, Inc.NCT01437566Written as GDC-0980
- A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedPhase 1Genentech, Inc.NCT00854126Written as GDC-0980
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female SubjectsCompletedPhase 1Genentech, Inc.NCT01487239Written as [14C]-GDC-0980
- Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980CompletedPhase 1Genentech, Inc.NCT01473316Written as GDC-0980
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedPhase 1Genentech, Inc.NCT00854152Written as GDC-0980
- A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial CarcinomaCompletedPhase 2Genentech, Inc.NCT01455493Written as GDC-0980
- Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted TherapyCompletedPhase 2Genentech, Inc.NCT01442090Written as GDC-0980
Given in every arm · 3 — apitolisib is usual care beside what is tested
- GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid TumorsCompletedPhase 1Genentech, Inc.NCT01332604Written as GDC-0980
- Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast CancerCompletedPhase 1Genentech, Inc.NCT01254526Written as GDC-0980
- A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid TumorsCompletedPhase 1Genentech, Inc.NCT01301716Written as GDC-0980
Codes
What other systems call apitolisib · ClinicalTrials.gg INT005981
- UNII (FDA) 1C854K1MIJAPITOLISIBConfirmed FDA, Wikidata
- Wikidata Q27074481apitolisibConfirmed FDA, Wikidata
- NCI Thesaurus C91731ApitolisibOne source FDA
- DrugBank DB12180One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1C854K1MIJ | APITOLISIB | Confirmed FDA, Wikidata |
| Wikidata | Q27074481 | apitolisib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C91731 | Apitolisib | One source FDA |
| DrugBank | DB12180 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.